Gsa Capital Partners LLP Y M Abs Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$4.86 - $7.23 $450,837 - $670,690	92,765 Added 208.3%	137,299 $748,000
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $664,418 - $1.21 Million	-116,975 Reduced 72.43%	44,534 $302,000
Q1 2023 May 12, 2023	BUY	$2.83 - $5.11 $176,447 - $318,603	62,349 Added 62.88%	161,509 $809,000
Q4 2022 Feb 13, 2023	BUY	$3.0 - $15.17 $297,480 - $1.5 Million	99,160 New	99,160 $484,000
Q1 2022 May 11, 2022	SELL	$6.55 - $17.42 $453,987 - $1.21 Million	-69,311 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $1.08 Million - $2.03 Million	69,311 New	69,311 $1.12 Million
Q4 2018 Feb 12, 2019	SELL	$15.41 - $28.92 $154,100 - $289,200	-10,000 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$24.0 - $26.97 $240,000 - $269,700	10,000 New	10,000 $266,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.